Nurses' Perspective of Treating Patients With an Amputation Due to Diabetic Foot Syndrome
Conclusions The results of this study highlight the key role that expert nurses play in the care of patients with DFS. Expert nurses considered that amputation leaves the individual physically and psychologically vulnerable, especially upon discharge from hospital. It is therefore essential to provide these patients with comprehensive and multidisciplinary care that includes emotional support.
Bigfoot Biomedical hasn't let the coronavirus pandemic stand in the way of bringing itsÂ injection-based digitized insulin dosing platform to the U.S. market. If anything, CEO Jeffrey Brewer says the pandemic has "only crystalized the need for medical solutions like ours that facilitate remote care, remote support, and home delivery." The company has raised a total of $55 million to close its series C equity financing.Â Abbott led the round with support from existing investors, including Quadrant Capital Advisors, Senvest Capital, Janus Henderson, and Cormorant Asset Management, along with n...
CONCLUSION: SHED combined with HBO therapy was effective for treating type 2 diabetic rats. The underlying mechanism may involve SHED-mediated increase in the proliferation and trans-differentiation of islet β -cells and decrease in pro-inflammatory cytokines and apoptosis of islets.
Conclusion FIB4A is a potential marker for early detection of NBNC-HCC in patients with diabetes mellitus. However, further studies are needed to confirm these findings.
Publication date: Available online 2 June 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Amerta Ghosh, Bhavya Arora, Ritesh Gupta, Shajith Anoop, Anoop Misra
Publication date: Available online 2 June 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Timur Ekiz, Ahmet Cemal Pazarlı
Publication date: Available online 2 June 2020Source: Canadian Journal of DiabetesAuthor(s): Sheri R. Colberg
Publication date: Available online 21 March 2020Source: Canadian Journal of DiabetesAuthor(s): Chantal L. Lemieux, Margaret deGroh, Laurie Gibbons, Howard Morrison, Ying Jiang
Publication date: September–October 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &Reviews, Volume 14, Issue 5Author(s): Hema S. Gopalan, Anoop Misra
Have type 1 diabetes and being forced to work during the pandemic? Here are the legal resources to know about.
Fractyl Laboratories is seeking to âturn back the clockâ in Type 2 diabetes progression with its disease-modifying therapy. FDA granted the Lexington, MA-based company IDE to launch a pivotal trial of the Revita DMR, a which holds the potential to eliminate the need for insulin injections in patients suffering from Type 2 diabetes. âInsulin is a challenging drug for patients with Type 2 diabetes because it can cause weight gain,â Harith Rajagopalan M.D. Ph.D., co-founder and CEO of Fractyl told MD+DI. âIt can cause a risk of your bloo...